What Matters Now
CME
Elevating Evidence-Aligned Multiple Myeloma Care: Frontline, Immunotherapy Sequencing, Follow-Up
Samir Parekh, MD, Mount Sinai
Oliver Van Oekelen, MD, PhD, Icahn School of Medicine at Mount Sinai
100% of Peers Changed Their Practice After this Clinical Scenario
CME
Deciding between triplet versus quadruplet frontline therapy for a transplant-eligible patient with t(4;14) and mild CKD amid efficacy versus tolerability and monitoring tradeoffs.
What Matters Now
CME
Elevating Evidence-Aligned Multiple Myeloma Care:
Frontline, Immunotherapy Sequencing, Follow-Up
Samir Parekh, MD, Mount Sinai
Oliver Van Oekelen, MD, PhD, Icahn School of Medicine at Mount Sinai
Corresponding Scenario
Holding the Quadruplet - Frontline Selection When Complexity Argues for Less
See experiences from 31 peers
Deciding between triplet versus quadruplet frontline therapy for a transplant-eligible patient with t(4;14) and mild CKD amid efficacy versus tolerability and monitoring tradeoffs.
How clinicians responded after this Clinical Scenario
92
%
begin unsure how to apply evidence
100
%
will implement a practice change
